New Buy Calls on PALI, LBRX, CCCC and DFTX: Targets, Cash and What the Analysts Are Betting On
Targets imply 88% to 314% upside, with cash into 2027-2030.
Already have an account? Sign in.
Targets imply 88% to 314% upside, with cash into 2027-2030.
Hims & Hers stock drops after missing revenue and subscriber expectations. Q3 revenue rose 49% to $890M, but margins compressed and guidance tightened.
Rocket Lab posted record $268M Q3 revenue and a $3.57B backlog, but shares dropped 5% after a wider-than-expected EPS miss.
The biotech’s initial JANX011 Phase 1 results in healthy volunteers triggered a sharp selloff as investors questioned near-term value and differentiation.
Be the first to know when deals break, stocks move, or biotech headlines hit.